Fine-Needle Mass Spectrometry for Rapid Lung Cancer Subtyping
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and subtyping lung cancer, particularly non-small cell lung cancer (NSCLC), face challenges due to inconclusive results from fine-needle aspiration biopsies, which are often subjective and time-consuming, and lack efficient techniques for distinguishing between adenocarcinoma (ADC) and squamous cell carcinoma (SCC) subtypes.
Innovation Solution
The use of desorption electrospray ionization mass spectrometry imaging (DESI-MSI) with a restricted mass range in negative ion mode to generate molecular profiles, combined with a statistical algorithm like Lasso logistic regression, for accurate classification of lung cancer subtypes from biopsy samples, enabling rapid and precise diagnosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional cytopathological examination and immunohistochemistry are used for lung cancer diagnosis and subtyping, then the diagnosis can be performed with standard equipment and procedures, but the results are subjective and take several days to a week to yield a final diagnosis
Solution Approach 1:
The patent replaces conventional mechanical and chemical staining methods (immunohistochemistry) with mass spectrometry imaging technology. This substitution enables direct molecular profiling of tissue samples without requiring subjective interpretation of stained slides, thereby reducing both diagnosis time and subjectivity while maintaining or improving diagnostic accuracy
Solution Approach 2:
The patent changes the measurement parameters from visual assessment of stained tissue sections to quantitative mass spectral data analysis. By measuring molecular profiles based on mass-to-charge ratios rather than visual staining patterns, the system achieves more objective and rapid subtyping of lung cancer specimens
2Ease of operation
If fine needle aspiration biopsy is performed to obtain lung tissue samples, then the procedure is minimally invasive, but the aspirated material is often insufficient for conclusive diagnosis and shows overlap between cytological features of lung cancer subtypes
Solution Approach 1:
The patent changes the analytical approach from examining cellular morphology (which shows overlap between subtypes) to analyzing molecular profiles via mass spectrometry. This parameter change enables conclusive diagnosis from the same limited FNA material that previously yielded inconclusive results
Solution Approach 2:
The patent introduces mass spectrometry imaging as an intermediary analytical technique between sample acquisition and final diagnosis. This intermediary method extracts molecular information from limited samples without requiring additional invasive procedures, bridging the gap between minimal sample collection and definitive diagnosis
3Measurement precision
If mass spectrometry imaging techniques are used to analyze lung cancer tissue sections, then direct and untargeted analysis with high chemical specificity and analytical sensitivity is enabled, but there has been limited effort evaluating the performance of these methods in clinical FNA samples
Solution Approach 1:
The patent makes the mass spectrometry imaging method universally applicable to multiple sample types including both tissue sections and fine needle aspiration samples. By demonstrating the technique's versatility across different clinical specimen formats, the patent bridges the gap between research-stage tissue analysis and clinical diagnostic applications
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach achieves high accuracy in diagnosing lung cancer and subtyping, with 100% diagnostic accuracy for lung cancer and 94.1% accuracy for subtyping in validation sets, significantly reducing diagnosis time and improving patient outcomes by guiding targeted therapies.
Implementation Method 1
performing desorption electrospray ionization mass spectrometry imaging (DESI-MSI) on the lung cancer sample
Data Source
AI summary
Methods for detecting lung cancer cells, or lung cancer subtypes, by measuring levels of metabolites are provided. Methods of treating identified cancers are likewise provided